医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Oxea Announces Price Increase for Carboxylic Acids

2013年01月05日 AM12:25
このエントリーをはてなブックマークに追加


 

DALLAS

Oxea will increase list and off-list prices on the product below effective January 15, 2013, or as contracts allow.

Product   North America   Asia, Middle East
    USD/lb USD/mt
2-Ethylhexanoic acid 0,03 100

Oxea is a global manufacturer of oxo intermediates and oxo derivatives, such as alcohols, polyols, carboxylic acids, specialty esters, and amines. These products are used for the production of high-quality coatings, lubricants, cosmetics and pharmaceutical products, flavorings and fragrances, printing inks and plastics. In 2011, Oxea generated revenue of about EUR 1.5 billion with its 1,365 employees in Europe, the Americas and Asia.

For more information, visit www.oxea-chemicals.com.

CONTACT

Commercial contact:
OXEA Corporation, 1505 West LBJ Freeway,
Dallas, TX, 75234, USA
Cristóbal Ascencio, Vice President
Oxo-Derivatives
Phone +1 972-481-2700, fax +1 972-481-6023
info@oxea-chemicals.com,
www.oxea-chemicals.com
or
Press
contact:

OXEA GmbH, Otto-Roelen-Strasse 3, D-46147 Oberhausen
Birgit
Reichel, phone +49 (0) 208-693-3112, fax +49 (0) 208-693-3101
birgit.reichel@oxea-chemicals.com,
www.oxea-chemicals.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • スミス・ディテクションのBioFlashが空中のCOVID-19を検出可能であることを実証
  • コロナ禍で生じたうつ病をいやす韓国産ペットケアロボット「ペディ」が人気
  • Korean Pet Care Robot PEDDY Gains Popularity to Relieve Pets’ Depression During COVID-19
  • Dr. Reddy’s Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market
  • Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists